Preprint: Artemisinin inhibits innate immune cell chemotaxis, cytokine production and NET release

Morad, H., Luqman, S., Pinto, L., Cunningham, K.P., Vilar, B., Clayton, G., Shankar-Hari, M. and McNaughton, P.A. 2022. Preprint: Artemisinin inhibits innate immune cell chemotaxis, cytokine production and NET release. https://doi.org/10.21203/rs.3.rs-1335980/v1

TitlePreprint: Artemisinin inhibits innate immune cell chemotaxis, cytokine production and NET release
AuthorsMorad, H., Luqman, S., Pinto, L., Cunningham, K.P., Vilar, B., Clayton, G., Shankar-Hari, M. and McNaughton, P.A.
Description

Immune cell chemotaxis to the sites of pathogen invasion is critical for fighting infection, but in life-threatening conditions such as sepsis and Covid-19, excess activation of the innate immune system is thought to cause a damaging invasion of immune cells into tissues and a consequent excessive release of cytokines. In these circumstances, tempering excessive activation of the innate immune system may, paradoxically, promote recovery. Here we identify the antimalarial compound artemisinin as a potent and selective inhibitor of neutrophil and macrophage chemotaxis induced by many chemotactic agents. Artemisinin released calcium from intracellular stores in a similar way to thapsigargin, a known inhibitor of the Sarco/Endoplasmic Reticulum Calcium ATPase pump (SERCA), but unlike thapsigargin, artemisinin blocks only the SERCA3 isoform. Inhibition of SERCA3 by artemisinin was irreversible and was inhibited by iron chelation, suggesting iron-catalysed alkylation of a specific cysteine residue in SERCA3 as the mechanism by which artemisinin inhibits immune cell motility. In murine infection models, artemisinin potently suppressed immune cell invasion into both peritoneum and lung in vivo and inhibited the release of cytokines/chemokines and neutrophil extracellular traps (NETs). This work suggests that artemisinin may have value as a therapy in conditions such as sepsis and Covid-19 in which over-activation of the innate immune system causes tissue injury that can lead to death.

Year2022
Output mediaResearch Square
Publication dates
PublishedFeb 2022
Digital Object Identifier (DOI)https://doi.org/10.21203/rs.3.rs-1335980/v1
Web address (URL)http://europepmc.org/abstract/PPR/PPR463045

Related outputs

Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism
Wu, X, Cunningham, K.P., Bruening-Wright, A, Pandey, S and Larsson, H. P. 2024. Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism. International Journal of Molecular Sciences. 25 (8) 4309. https://doi.org/10.3390/ijms25084309

Preprint: Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism
Xiaoan Wu, Kevin P. Cunningham, Andrew Bruening-Wright, Shilpi Pandey and H. Peter Larsson 2024. Preprint: Loose Coupling between the Voltage Sensor and the Activation Gate in Mammalian HCN Channels Suggests a Gating Mechanism. Preprints.org. https://doi.org/10.20944/preprints202403.0499.v1

Preprint: Binding of PUFA stabilizes a conductive state of the selectivity filter in IKs channels
Alessia Golluscio, Jodene Eldstrom, Jessica J. Jowais, Marta E. Perez-Rodriguez, Kevin P. Cunningham, Alicia de la Cruz, Xiaoan Wu, David Fedida and H. Peter Larsson 2024. Preprint: Binding of PUFA stabilizes a conductive state of the selectivity filter in IKs channels. arXiv. https://doi.org/10.1101/2024.01.11.575247

Similar voltage-sensor movement in spHCN channels can cause closing, opening, or inactivation
Xiaoan Wu, Kevin P. Cunningham, Rosamary Ramentol, Marta E. Perez and H. Peter Larsson 2023. Similar voltage-sensor movement in spHCN channels can cause closing, opening, or inactivation. Journal of General Physiology. 155 (5) e202213170. https://doi.org/10.1085/jgp.202213170

The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
Cunningham, K., Clapp. L.H., Mathie, A. and Veale, E.L. 2021. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels. Frontiers in Pharmacology. 12 705421. https://doi.org/10.3389/fphar.2021.705421

Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond.
Mathie, A., Veale, E.L., Cunningham, K.P., Holden, R.G. and Wright, P.D. 2021. Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond. Annual Review of Pharmacology and Toxicology. 61, pp. 401-420. https://doi.org/10.1146/annurev-pharmtox-030920-111536

Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channels
Kevin P. Cunningham, D. Euan MacIntyre, Alistair Mathie and Emma L. Veale 2020. Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channels. Acta Physiologica. 228 (2) e13361. https://doi.org/10.1111/apha.13361

Characterization and regulation of wild‐type and mutant TASK‐1 two pore domain potassium channels indicated in pulmonary arterial hypertension
Cunningham, K.P., Holden, R.G., Escribano‐Subias, P.M., Cogolludo, A., Veale, E.L. and Mathie, A. 2019. Characterization and regulation of wild‐type and mutant TASK‐1 two pore domain potassium channels indicated in pulmonary arterial hypertension. Journal of Physiology. 597 (4), pp. 1087-1101. https://doi.org/10.1113/jp277275

Permalink - https://westminsterresearch.westminster.ac.uk/item/w3yz1/preprint-artemisinin-inhibits-innate-immune-cell-chemotaxis-cytokine-production-and-net-release


Share this

Usage statistics

25 total views
0 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.